{"DataElement":{"publicId":"3151968","version":"1","preferredName":"Patient Primary Neoplasm Negative Finding WT1 Protein Estrogen Receptor Eligibility Determination Ind-2","preferredDefinition":"the yes/no indicator related to criteria to determine eligibility of patients for medical care programs and services based on primary tumor showing lack of immunoreactivity or negative for expression of WT-1 antigen (a potential regulator of transcription, WT1 belongs to the EGR family of C2H2 zinc-finger proteins and binds to the DNA sequence 5'-CGCCCCCGC-3') and Estrogen Receptor (cytoplasmic hormone-activated receptors that act as nuclear transcription factors composed of an N-terminal transcription activation/modulation domain, a DNA-binding domain, and a C-terminal steroid-binding domain) antigen.","longName":"3151965v1.0:2018257v1.0","context":"CTEP","contextVersion":"2.31","DataElementConcept":{"publicId":"3151965","version":"1","preferredName":"Patient Primary Neoplasm Negative Finding WT1 Protein Estrogen Receptor Eligibility Determination","preferredDefinition":"information related to criteria to determine eligibility of patients for medical care programs and services based on primary tumor showing lack of immunoreactivity or negative for expression of WT-1 antigen (a potential regulator of transcription, WT1 belongs to the EGR family of C2H2 zinc-finger proteins and binds to the DNA sequence 5'-CGCCCCCGC-3') and Estrogen Receptor (cytoplasmic hormone-activated receptors that act as nuclear transcription factors composed of an N-terminal transcription activation/modulation domain, a DNA-binding domain, and a C-terminal steroid-binding domain) antigen.","longName":"2233604v1.0:3151963v1.0","context":"CTEP","contextVersion":"2.31","ObjectClass":{"publicId":"2233604","version":"1","preferredName":"Patient","preferredDefinition":"A person who requires medical care.","longName":"C16960","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Patient","conceptCode":"C16960","definition":"A person who receives medical attention, care, or treatment, or who is registered with medical professional or institution with the purpose to receive medical care when necessary.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"F95D94B9-D847-2792-E034-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-06-13","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2005-06-13","modifiedBy":"ONEDATA","dateModified":"2005-06-13","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"3151963","version":"1","preferredName":"Primary Neoplasm Negative Finding WT1 Protein ER Eligibility Determination","preferredDefinition":"The original tumor.:A finding of normality following an examination or investigation looking for the presence of a microorganism, disease, or condition.:A potential regulator of transcription, WT1 belongs to the EGR family of C2H2 zinc-finger proteins and binds to the DNA sequence 5'-CGCCCCCGC-3'. Inactivation of WT1 is one cause of Wilm's Tumor, an embryonal malignancy of the kidney. Defects in WT1 are also associated with Denys-Drash Syndrome (DDS) and Diffuse Mesangial Sclerosis (DMS). (from SWISS-PROT P19544, OMIM 194070, and NCI):Widely expressed human Estrogen Receptors (NR3 Family) are ligand-activated nuclear hormone receptor transcription factors composed of an N-terminal transcription activation/modulation domain, a DNA-binding domain, and a C-terminal steroid-binding domain. Binding to DNA as a homo- or heterodimer, ESR interacts with NCOA3, NCOA5, and NCOA6 coactivators. Hormone-ESR complexes appear to recognize discrete upstream target ERE DNA sequences to regulate gene expression, cell proliferation, and differentiation. DNA-binding is lost in the absence of ligand. (NCI):Criteria to determine eligibility of patients for medical care programs and services.","longName":"3151963v1.0","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Primary Neoplasm","conceptCode":"C8509","definition":"A tumor at the original site of origin.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"4"},{"longName":"Negative Finding","conceptCode":"C38757","definition":"A finding of normality following an examination or investigation looking for the presence of a microorganism, disease, or condition.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"3"},{"longName":"Wilms Tumor Protein","conceptCode":"C17549","definition":"Wilms tumor protein (449 aa, ~49 kDa) is encoded by the human WT1 gene. This protein is involved in transcriptional regulation, embryonic morphogenesis and in both tumor suppression and tumorigenesis.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Estrogen Receptor Family","conceptCode":"C17069","definition":"Widely expressed human Estrogen Receptors (NR3 Family) are cytoplasmic hormone-activated receptors that act as nuclear transcription factors composed of an N-terminal transcription activation/modulation domain, a DNA-binding domain, and a C-terminal steroid-binding domain. Binding to DNA as a homo- or heterodimer, ESR interacts with NCOA3, NCOA5, and NCOA6 coactivators. Hormone-ESR complexes appear to recognize discrete upstream target ERE DNA sequences to regulate gene expression, cell proliferation, and differentiation. DNA-binding is lost in the absence of ligand. (NCI)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Eligibility Determination","conceptCode":"C25171","definition":"The act of determining if a subject is suitable for enrollment in a study according specific protocol criteria and procedures.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"930EFA1C-EBC3-AE77-E040-BB89AD434653","latestVersionIndicator":"Yes","beginDate":"2010-10-20","endDate":null,"createdBy":"ALAIS","dateCreated":"2010-10-20","modifiedBy":"ONEDATA","dateModified":"2010-10-20","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008525","version":"1","preferredName":"Eligibility","preferredDefinition":"trial-specific criteria that a patient must meet to be enrolled.","longName":"ELIG","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B1EC3968-9F25-305A-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-16","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-16","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"GOG CRF:Gynecologic Oncology Group Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"930EFA1C-EBD4-AE77-E040-BB89AD434653","latestVersionIndicator":"Yes","beginDate":"2010-10-20","endDate":null,"createdBy":"ALAIS","dateCreated":"2010-10-20","modifiedBy":"SBR","dateModified":"2016-06-06","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"3506068","version":"1","preferredName":"Yes No Indicator","preferredDefinition":"The preferred Value Domain to indicate a question with permissible values of yes/no.","longName":"YES_NO_IND","context":"NCI Standards","contextVersion":"1","type":"Enumerated","dataType":"CHARACTER","minLength":"2","maxLength":"3","minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[{"value":"No","valueDescription":"No","ValueMeaning":{"publicId":"3197154","version":"1","preferredName":"No","longName":"3197154","preferredDefinition":"The non-affirmative response to a question.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"No","conceptCode":"C49487","definition":"The non-affirmative response to a question.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9D865DE5-55AD-1AC9-E040-BB89AD436B4F","latestVersionIndicator":"Yes","beginDate":"2011-03-02","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2011-03-02","modifiedBy":"SOKKERL","dateModified":"2023-12-05","changeDescription":null,"administrativeNotes":"2022.12.28 Alt VM added per ticket request CADSR0001837. aj","unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"C37A1BEB-75C2-B6C9-E040-BB89AD434179","beginDate":"2012-06-27","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2012-06-27","modifiedBy":"ONEDATA","dateModified":"2012-06-27","deletedIndicator":"No"},{"value":"Yes","valueDescription":"Yes","ValueMeaning":{"publicId":"3197153","version":"1","preferredName":"Yes","longName":"3197153v1.00","preferredDefinition":"The affirmative response to a question.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Yes","conceptCode":"C49488","definition":"The affirmative response to a question.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9D865DE5-558A-1AC9-E040-BB89AD436B4F","latestVersionIndicator":"Yes","beginDate":"2011-03-02","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2011-03-02","modifiedBy":"SOKKERL","dateModified":"2023-12-05","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"C37A1BEB-75CC-B6C9-E040-BB89AD434179","beginDate":"2012-06-27","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2012-06-27","modifiedBy":"ONEDATA","dateModified":"2012-06-27","deletedIndicator":"No"}],"ConceptualDomain":{"publicId":"3502157","version":"1","preferredName":"Yes No Indicator Value Domains","preferredDefinition":"Conceptual domain that includes value meanings to be used for Indicator Value Meanings such as Yes, No, Unknown, No Applicable","longName":"YES_NO_IND_VD","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"C377DE0C-8C3E-DCA8-E040-BB89AD431B6D","latestVersionIndicator":"Yes","beginDate":"2012-06-27","endDate":null,"createdBy":"CURTIST","dateCreated":"2012-06-27","modifiedBy":"CURTIST","dateModified":"2012-06-27","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"2421125","version":"1","preferredName":"Ind-2","preferredDefinition":"A caDSR representation term that is used to indicate a question with permissible values of yes/no","longName":"C38147","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Yes or No Response","conceptCode":"C38147","definition":"A response or indicator that can have a value of either yes or no.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RETIRED ARCHIVED","registrationStatus":"Retired","id":"0303DF01-F4B4-15EC-E044-0003BA3F9857","latestVersionIndicator":"No","beginDate":"2005-10-18","endDate":"2016-04-27","createdBy":"SHIDED","dateCreated":"2005-10-18","modifiedBy":"TAYLORT","dateModified":"2020-10-03","changeDescription":"10.3.20 TL changed WFS from RETIRED PHASED OUT to RETIRED ARCHIVED. Changed Workflow Status DBW 04-27-2016","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Standard","id":"C37A1BEB-75AE-B6C9-E040-BB89AD434179","latestVersionIndicator":"Yes","beginDate":"2012-06-27","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2012-06-27","modifiedBy":"TSESU","dateModified":"2023-08-16","changeDescription":"8/29/17 tt added CSI per Round 5 finalization task. 3/12/17 jk added Standard reg status; ownership transfered from CTEP to NCI Standards with concurrence of CTEP/Brian Campbell. jk","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[{"publicId":"4057943","version":"1","longName":"Disease Site","context":"NRG","ClassificationSchemeItems":[{"publicId":"4104940","version":"1","longName":"GOG-0268","context":"NRG"}]}],"AlternateNames":[{"name":"3151965v1.0:2018257v1.0","type":"USED_BY","context":"NRG"}],"ReferenceDocuments":[{"name":"Are there representative stai","type":"Preferred Question Text","description":"Are there representative stained slides available from the primary tumor showing lack of immunoreactivity or negative for expression of WT-1 antigen and Estrogen Receptor (ER) antigen by immunohistochemistry?","url":null,"context":"CTEP"}],"origin":"GOG CRF:Gynecologic Oncology Group Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"930EFA1C-EBF8-AE77-E040-BB89AD434653","latestVersionIndicator":"Yes","beginDate":"2010-10-20","endDate":null,"createdBy":"ALAIS","dateCreated":"2010-10-20","modifiedBy":"FORMBUILDER","dateModified":"2014-09-02","changeDescription":"Replaced VD Eligibility Ind-2 2018257v1 with VD ID#3506068 - Yes No Indicator - dbw","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"}}